DalsnaFinance

PD-L1 Biomarker Testing Market to Reach USD 1,830.7 Million by 2036 as Precision Oncology and Immunotherapy Adoption Accelerate Global Demand

Markets PR Newswire By PR Newswire 16 Jun 2026 14:01 1 min read
PD-L1 Biomarker Testing Market to Reach USD 1,830.7 Million by 2036 as Precision Oncology and Immunotherapy Adoption Accelerate Global Demand

NEWARK, Del., June 16, 2026 /PRNewswire/ -- The global PD-L1 Biomarker Testing Market is witnessing robust expansion as precision oncology, immunotherapy adoption, and biomarker-driven treatment selection continue reshaping cancer diagnostics. According to the latest analysis by Future...

NEWARK, Del., June 16, 2026 /PRNewswire/ -- The global PD-L1 Biomarker Testing Market is witnessing robust expansion as precision oncology, immunotherapy adoption, and biomarker-driven treatment selection continue reshaping cancer diagnostics. According to the latest analysis by Future...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.